Lightlake Therapeutics Inc. Finishing Patient Testing in Phase II Trial of Patented Binge Eating Disorder Treatment
20 März 2012 - 1:45PM
Marketwired
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company" or
"Lightlake"), an early stage biopharmaceutical company developing
modern addiction treatments based on its expertise using opioid
antagonists, announced today that the last patient involved in the
Phase II Trial of the Company's proprietary treatment for Binge
Eating Disorder is scheduled to be seen on March 27th, with the
statistical analysis of the results of the Trial taking place
thereafter.
"Completing this Phase II Trial will mark a major milestone for
us," said Dr. Roger Crystal, Chief Executive Officer of Lightlake.
"Our innovative nasal spray treatment has the potential to
considerably improve the quality of life of those patients
suffering from Binge Eating Disorder, which is the most common
eating disorder in the U.S., affecting more than eight million
people and accounting for three times the number of those diagnosed
with anorexia and bulimia together."
Lightlake randomly selected 138 patients whom met the criteria
for Binge Eating Disorder from over 900 applicants wanting to
participate in the Phase II Trial, which is being held in Helsinki,
Finland. Crown CRO, a Finnish Contract Research Organization
involved in approximately 300 clinical studies over the years in
addition to 90 clinical trials currently in progress, is providing
the external validation for the Trial and Hannu Alho, professor of
addiction medicine at the University of Helsinki, is serving as the
lead investigator.
About Lightlake Therapeutics, Inc.
Lightlake Therapeutics Inc. is a developing biopharmaceutical
company aiming to build a platform of biopharmaceutical solutions
to common addictions and related disorders. Currently, the Company
is focused on providing a safe, effective and simple treatment for
patients who are obese or overweight as a result of Binge Eating
Disorder in addition to those patients suffering from Bulimia
Nervosa. Lightlake recently acquired patents that will allow it to
widen its product pipeline to address patients with addictions to
opioid painkillers, methadone, cocaine and amphetamine. The Company
anticipates launching a development program for each of these
purposes in the future.
Safe Harbor
This press release contains forward-looking statements. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes," estimates," "predicts," "projects,"
"potential" or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based
on our current expectations and projections about future events.
You should not place undue reliance on these statements. Actual
events or results may differ materially. In evaluating these
statements, you should specifically consider various factors. These
and other factors may cause our actual results to differ materially
from any forward- looking statement. We undertake no obligation to
update any of the forward-looking statements after the date of this
presentation to conform those statements to reflect the occurrence
of unanticipated events, except as required by applicable law.
Investor Contact: Mr. Kevin Fickle President NUWA Group LLC Tel:
+1-925-330-8315 Email: kevin@nuwagroup.com Company Contact: Dr.
Roger Crystal Lightlake Therapeutics Inc. Tel: +44(0)-207-034-1943
Email: roger.crystal@lightlaketherapeutics.com
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024